- Women can miss out on work with aggressive breast cancer surgery
- Women who underwent a bilateral mastectomy experienced 8-times higher risk of missing work than lumpectomy patients
- 29% of Bilateral mastectomy patients lost more than $5000 on missing more than a months work.
Aggressive breast cancer surgery can cause you to miss more out on work found a new study published in cancer journal.
Many women with breast cancer are working at the time of diagnosis and would benefit from understanding how their treatment decisions might affect their employment.
To examine how employment experiences are impacted by different types of breast cancer treatment, Reshma Jagsi, MD, DPhil, of the University of Michigan, and her colleagues surveyed women aged 20 to 79 years diagnosed with stages 0-II breast cancer as reported to the Georgia and Los Angeles SEER registries in 2014 and 2015.
The study's findings also revealed that women who underwent bilateral mastectomy with reconstruction had nearly eight times the risk of missing over a month of work, as compared with those who underwent lumpectomy.
Also, women who missed more than a month of work often lost substantial income; 29 percent of these women lost more than $5000.
"Prior studies have shown that most of the women who had bilateral mastectomy could have chosen lumpectomy but chose the more aggressive surgery, often out of a desire to improve peace of mind.
This study helps to quantify the impact of this decision on the employment and financial experiences of those women soon after diagnosis," said Dr. Jagsi.
"The impact of treatment on employment and finances is a consideration that women may wish to take into account when weighing the pros and cons of various surgical options they are considering."
- Reshma Jagsi, Paul Abrahamse, Kamaria L. Lee, Lauren P. Wallner, Nancy K. Janz, Ann S. Hamilton, Kevin C. Ward, Monica Morrow, Allison W. Kurian, Christopher R. Friese, Sarah T. Hawley,and Steven J. Katz.. Treatment decisions and the employment of breast cancer patients, CANCERDOI: 10.1002/cncr.30959